Eton Pharmaceuticals, Inc. · NASDAQ:ETON

Eton Pharmaceuticals — Investor Presentation (December 2024)

18 slides from Eton Pharmaceuticals's investor presentation, December 2024

  1. Slide 1: Reimagining Molecules to Advance Medicine

    Reimagining Molecules to Advance Medicine Corporate Presentation – December 2024 ©2024 Eton Pharmaceuticals. All rights reserved. 1

  2. Slide 2: Safe Harbor

    Safe Harbor SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This document contains forward-looking statements concerning Eton Pharmaceuticals, Inc. (“Eton”, the “Company,” “we,” “us,” and “our”). The words “believe,” “may,” “will,” “potentially,” “estimate,” “continue,” “anticipate,” “intend,” “co

  3. Slide 3: Investment Highlights

    Investment Highlights Dedicated to developing and commercializing pharmaceutical products to address unmet needs in patients suffering from extremely rare conditions Focus on bringing treatments to patients with the ULTRA-RARE DISEASE FOCUS rarest of conditions (<10,000 patients) Therapeutic areas o

  4. Slide 4: Why Ultra-Rare?

    Why Ultra-Rare? TARGETED LARGE OPPORTUNITY MEANINGFUL IMPACT COMMERCIALIZATION LIMITED COMPETITION More than 5,000 rare Eton prefers markets where Small patient populations Many companies are diseases have no FDA- it can provide the first or have small prescriber unwilling to dedicate approved treat

  5. Slide 5: Ultra-Rare Commercialization

    Ultra-Rare Commercialization Eton’s commercial strategy is designed to serve the unique needs of ultra-rare patient populations Concentrated prescriber bases. Small number of specialists within pediatric endocrinology and metabolic genetics allows for an efficient twelve-person sales force to cover

  6. Slide 6: 15 Straight Quarters of Product Revenue Growth

    15 Straight Quarters of Product Revenue Growth STRONG 2024 YTD PERFORMANCE 3 PART STRATEGY FOR LONG-TERM REVENUE GROWTH • YTD 2024 product revenue* up 44% year-over-year • Net income and operating cash flow positive in Q3 Continued organic growth 2024 of ALKINDI SPRINKLE Grow (2034 IP), Carglumic Ac

  7. Slide 7: Path to 10 Commercial Products by 2025

    Path to 10 Commercial Products by 2025 CMC Phase III/ NDA Commercial Development Pivotal Study Submission 1 ALKINDI SPRINKLE® - Pediatric Adrenal Insufficiency 2 Increlex® - Primary Insulin-Like Growth Factor 1 Deficiency Long-term goal of 10 commercial 3 Carglumic Acid - Hyperammonemia rare disease

  8. Slide 8: ALKINDI SPRINKLE®

    ALKINDI SPRINKLE® ALKINDI SPRINKLE® is a proprietary formulation of hydrocortisone sprinkles that is FDA approved as a replacement therapy for adrenocortical insufficiency (AI) in patients under 17 years of age • First and only hydrocortisone treatment specifically designed to help provide accurate

  9. Slide 9: NDA Submitted: ET-400

    NDA Submitted: ET-400 NDA accepted for ET-400 (hydrocortisone oral solution) with February 28, 2025 PDUFA date Highly requested dosage form. ET-400 will provide an additional oral hydrocortisone treatment option. Patients and caregivers have expressed strong demand for an FDA-approved liquid formula

  10. Slide 10: Pending Acquisition: INCRELEX®

    Pending Acquisition: INCRELEX® Eton executed an agreement to acquire Increlex® global rights from Ipsen in October 2024. Transaction expected to close near year-end 2024 Treats Severe Primary IGF-1 Deficiency, which causes short stature in children and adolescents. It is estimated that approximately

  11. Slide 11: PKU GOLIKE®

    PKU GOLIKE® Acquired U.S. rights to PKU GoLike, a medical formula for patients with phenylketonuria (PKU), in March 2024 Controlled-release, taste- and odor-masked amino acid mix. Designed to provide a better taste and a superior experience compared to alternative PKU medical formulas. Available in

  12. Slide 12: Additional Metabolic Genetics Portfolio

    Additional Metabolic Genetics Portfolio Three approved generic products prescribed by metabolic geneticists Lower cost alternatives to very expensive rare disease products. For some patients, the cost of Carbaglu® can exceed $1 million per year. Promoted by Eton’s sales force with full patient suppo

  13. Slide 13: Under Development: ET-600

    Under Development: ET-600 Product candidate under development for the treatment of diabetes insipidus Addresses significant unmet need for an orphan patient population. The condition is estimated to impact less than 5,000 pediatric patients in the United States. Synergistic fit in Eton’s portfolio.

  14. Slide 14: Under Development: ZENEO® Hydrocortisone Autoinjector

    Under Development: ZENEO® Hydrocortisone Autoinjector ZENEO® hydrocortisone autoinjector is under development as a rescue treatment for adrenal crisis Solves a major hurdle to current treatment. Current treatment, Solu- Cortef®, must be diluted, mixed, and administered with a standard syringe. Eton’

  15. Slide 15: Investment Summary

    Investment Summary ATTRACTIVE PROVEN ABILITY TO WELL-CAPITALIZED TO NEAR-TERM PORTFOLIO AND ACCELERATE GROWTH FUND GROWTH CATALYSTS PIPELINE POISED FOR THROUGH ACQUISITIONS LONG-TERM GROWTH & LICENSING • ET-600 pivotal study in Q4 • 15 straight quarters of • Favorable acquisition • $20.3 million of

  16. Slide 16: Appendix

    Appendix 16 ©2024 Eton Pharmaceuticals. All rights reserved.

  17. Slide 17: Experienced Leadership Team

    Experienced Leadership Team Our leadership team brings a proven track record of successfully developing and commercializing products at industry leading companies 17 ©2024 Eton Pharmaceuticals. All rights reserved.

  18. Slide 18: ©2024 Eton Pharmaceuticals. All rights reserved.

    ©2024 Eton Pharmaceuticals. All rights reserved. 18

Eton Pharmaceuticals — Investor Presentation (December 2024) on 6ix